TürkiyeResearch and clinical trials
Türkiye iTTP registry: response rate of 79.9% in 215 patients at 19 centers
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In Türkiye, 215 patients from 19 hematology centers were enrolled in the registry. The median age at diagnosis was 41. The most common symptoms were fatigue and headache. Plasma exchange was the treatment used most often. Of the patients, 79.9% responded to treatment. During follow-up, the disease flared up again in 35 patients.
What does it mean for patients and families?
This registry shows the real-world treatment picture in Türkiye. Because the disease can come back, regular check-ups are important. This is an interim analysis.
Source
Scientific paper: Clinical Manifestations, Treatment Characteristics, and Clinical Outcomes in Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP) in a Real-World Setting: An Interim Analysis of the Turkish iTTP Registry. Turkish Journal of Haematology, 2025. DOI: 10.4274/tjh.galenos.2025.2025.0134 · PubMed 40699136
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Thrombotic thrombocytopenic purpura (TTP)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.